Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amelgen 400 mg BID vs TID for Luteal Support in IVF
NCT04806919Phase 3Completed
- Sponsor
- Ghent University Hospital
- Start
- Apr 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of progesterone in luteal phase defect (LPD), spontaneous abortion, sponsored by Ghent University Hospital. Started Apr 2021; status: completed.
02
Drugs
progesterone
03
Conditions
luteal phase defect (LPD)spontaneous abortion
Beyond the preview
Go deeper on NCT04806919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806919.